Navigation Links
Surveillance may be suitable treatment option for patients with low-risk prostate cancer
Date:6/18/2010

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

Treatment of localized prostate cancer is controversial because, for some, this disease will not progress during their life time, and treatment may incur serious and long-lasting side effects. An increasingly popular option is active surveillance, or deferring treatment until evidence of disease progression.

To investigate outcomes of patients treated with active surveillance, Pr Stattin, M.D., of the Department of Surgical and Perioperative Science at Umea University, and colleagues conducted an observational study of 6849 patients in the National Prostate Cancer Register of Sweden with localized prostate cancer who were 70 years old or younger. The patients had low or intermediate risk of prostate cancer progression and were treated with active surveillance or watchful waiting; or radical prostatectomy or radiation therapy from 1997 through December 2002.

In this cohort, 2021 patients received surveillance, 3399 received radical prostatectomy, and 1429 received radiation therapy. After a median follow-up of 8.2 years, there were 413 deaths in the surveillance group; 286 in the radical prostatectomy group, and 1429 patients in the radiation therapy group. The researchers found a much higher percentage of death from competing causes in the surveillance group (19.2%, compared with 6.8% in the prostatectomy group and 10.9% in the radiation therapy group), suggesting that patients with a shorter life expectancy were more often selected for surveillance than surgery or radiation therapy.

This observational study found that the risk of calculated cumulative prostate cancer-specific death was lower among patients in the prostatectomy group than those in the surveillance group. However, the difference in absolute risk between the groups was modest, at 1.2%, after 10 years of follow-up.

The authors conclude that surveillance is the best strategy for many patients with low-risk prostate cancer. "With a 10-year prostate cancer-specific mortality of less than 3% for patients with low-risk prostate cancer on surveillance, this strategy appears to be suitable for many of these men," they write.

In an accompanying editorial, Siu-Long Yao and Grace Lu-Yao of The Cancer Institute of New Jersey write that perhaps the most remarkable result of this and other recent studies is that survival among most patients with localized disease managed conservatively is now similar to that of control subjects of similar ages.

Indeed, most men will die of another disease, and a prostate cancer diagnosis should act as a wake-up call for men to take charge of their healthcare and take better care of themselves. However, the authors write that a significant challenge is that, "A bevy of cancer research has demonstrated that cancer patients are particularly receptive to health-care advice after diagnosis, although older men, like those with prostate cancer, appear to be less receptive to change."


'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Genomic surveillance of pandemic H1N1
2. Pitt researchers raise concern over frequency of surveillance colonoscopy
3. AMP Receives Grant From the Bill & Melinda Gates Foundation to Support Cholera Surveillance in Africa
4. CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking
5. AGA offers new recommendations for CRC surveillance for certain patients with IBD
6. NHLBI, CDC launch surveillance and research program for inherited blood diseases
7. Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters
8. CMS to Present Surveillance Activities in Contract Year 2010 During the Connecture Sponsored Webinar on April 7
9. neXante Turns Apple's iPhone Into Skin Cancer Surveillance Support Tool And Health Record
10. Study finds poor compliance with cirrhosis surveillance recommendations
11. Kidneys From Older Donors Suitable for Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, ... experience for hospitalized patients and their practitioners, announced today ... in funding. Velano will use the proceeds from this ... financing completed in January 2015, to support the development ... adult and pediatric populations. Philadelphia ...
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
Breaking Medicine Technology: